SAN JOSE, Calif., Jan. 21 /PRNewswire-FirstCall/ -- Human Pheromone Sciences, Inc. (OTC Bulletin Board: EROX) ("HPS" or "the Company") announced that it has established a website devoted to its newly-announced mood- enhancing compound, ER 303, for which the Company filed Comprehensive Patent Applications with both the U.S. Patent and Trademark Office and the International Bureau of the World Patent Office. On the site, the Company released additional data regarding the testing that was performed on male and female volunteers, which show significant improvement in several aspects of mood enhancement.
"We felt it appropriate to develop this website to respond to requests received about this innovative and previously undeveloped compound, with its origin in sea coral, which has significant emotional impacts on both men and women, enhancing feelings of positive social relationships, personal well- being and social attraction", a Company spokesperson noted. "Hopefully, the data contained on this site will answer initial questions that have been posed since the Company's original announcement", the spokesperson indicated.
In addition to the Company's earlier disclosure, the data included on http://www.ER303.com details the definitive results of the testing that was performed, and confirms that prior to the Company's reproduction of this naturally-occurring compound, it could only be found in coral reefs off the coasts of Newfoundland and in the waters off Brazil's Guiabinha Island.
The Company has previously been granted broad-based worldwide patents for its initial compound, Androstadienone, which has been licensed to leading marketers, including Johnson & Johnson, Avon and Schwarkopf and Henkel and its affiliates.
This news release may contain forward-looking statements that involve risks and uncertainties that could cause results to differ from predicted results. Further information on factors that could affect the Company's results is detailed in the Company's annual report to shareholders on Form 10- KSB for the year ended December 31, 2007, and Form 10-Q for the nine months ended September 30, 2008 as filed with the Securities and Exchange Commission. The Company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements.
|SOURCE Human Pheromone Sciences, Inc.|
Copyright©2009 PR Newswire.
All rights reserved